Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD4635 + Cabazitaxel + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD4635||AZD 4635|AZD-4635||Adenosine Targeting 22||AZD4635 binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 32727810).|
|Cabazitaxel||Jevtana||XRP6258|RPR-116258A||Antimicrotubule Agent 14||Jevtana (cabazitaxel) inhibits microtubule depolymerization by binding to tubulin, resulting in cell cycle arrest and decreased tumor cell proliferation (PMID: 32660451).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 106||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04495179||Phase II||AZD4635 + Durvalumab AZD4635 + Cabazitaxel + Durvalumab||A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC)||Completed||USA | FRA | ESP | BEL||1|